Not Yet RecruitingPhase 2

A Study to Evaluate Pharmacokinetics (PK) and Safety of Subcutaneous (SC) Ublituximab Administered at Various Injection Sites and Relative Bioavailability Via Autoinjector (AI) Versus Syringe Subcutaneously in Participants With Multiple Sclerosis (MS)

350 participantsStarted 2026-03-21

Plain-language summary

The purpose of this study is to evaluate the PK and safety of ublituximab SC at different sites of administration and relative bioavailability of ublituximab SC with an AI device versus syringe.

Who can participate

Age range18 Years – 65 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Diagnosis of relapsing multiple sclerosis (RMS) (2017 Revised McDonald criteria).
✓. Expanded Disability Status Scale (EDSS) score less than or equal to (≤) 5.5 at screening.
✓. Neurologically stable for more than (\>) 30 days prior to screening and Day 1.
✓. Female participants of childbearing potential must consent to use an effective method of contraception from consent and for 6 months after the last dose of ublituximab.

Exclusion criteria

✕. Primary-progressive multiple sclerosis (PPMS) or inactive secondary progressive multiple sclerosis (SPMS).
✕. Active chronic disease of the immune system other than MS or immunodeficiency syndrome.
✕. Participants with significantly impaired bone marrow function or significant leukopenia or thrombocytopenia.
✕. Participants who received any approved therapy to treat MS within 5 half-lives of the medication prior to screening.
✕. Treatment with any investigational agent within 5 half-lives of the investigational drug prior to screening.
✕. Females who are pregnant or nursing.

What they're measuring

Part 2: Area under the curve (AUC) From Week 0 to Week 12 [AUC(0-W12)] of Ublituximab

Timeframe: Up to Week 12

Trial details

NCT IDNCT07503873

SponsorTG Therapeutics, Inc.

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2027-07-31

Contact for this trial

TG Therapeutics Clinical Support Team

1-877-575-8489 clinicalsupport@tgtxinc.com

View on ClinicalTrials.gov More Multiple Sclerosis trials